NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

NovoCure LimitedNASDAQ: NVCR

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $18.67M (cash outflow) fell 59.7% year over year, behind the -33.4% change in trailing-twelve-month free cash flow. Sequentially, it fell 18.5% from the prior quarter.

Context

  • Free cash flow amounted to 11.5% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Free cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -59.7% toward the trailing-twelve-month pace of -33.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.67M-18.5% QoQ
Last fiscal yearDec 2025
-$75.68M+9.3% YoY
LTMMar 2026
-$48.07M-33.4% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.7%——
1 year+9.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(75.68M) USD
Year-over-year change
-9.3%

Free Cash Flow vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 free cash flow of $48.07M is the 2nd largest of the 4 companies compared; the peer median is $9.84M.
  • Its year-over-year change of -33.4% is the 3rd highest of 4, against a peer median of +37.2%.
  • Free cash flow amounts to 7.1% of revenue for NVCR, versus a peer median of 21.2%.
NVCR Competitors Peer median
Free Cash Flow for NVCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLSEPulse Biosciences, Inc.LTM Jun 2026$61.39M +37.2%+4.7%5180.4%
NVCRNovoCure LimitedLTM Mar 2026$48.07M -33.4%—7.1%
DCTHDelcath Systems, Inc.LTM Mar 2026$19.19M +353.2%—21.2%
NPCENeuroPace, Inc.LTM Mar 2026$9.84M -45.8%-32.9%9.9%
Peer median (excluding NVCR) $9.84M+37.2%-14.1%21.2%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Depreciation & Amortization10.25M10.62M10.97M(14.41M)14.65M
Deferred Income Tax3.88M0000
Stock-Based Compensation94.9M106.96M115.61M160.04M0
Change in Working Capital29.07M11.8M29.56M(4.3M)(15.13M)
Accounts Receivables5.27M2.55M29.41M(26.36M)(38.94M)
Inventory2.48M(4.34M)(8.92M)2.57M(5.67M)
Accounts Payables27.78M14.26M14.87M19.11M18.96M
Other Working Capital(6.46M)(666K)(5.8M)384K10.52M
Other Non-Cash Items3.01M(6.05M)(22.43M)932K87.67M
Operating Cash Flow82.76M30.79M(73.34M)(26.37M)(49.03M)
Capital Expenditures(24.17M)(21.36M)(27.09M)(42.86M)(26.65M)
Acquisitions (Net)120.66M118.6M000
Purchases of Investments(1.08B)(1.3B)(1B)(875.39M)(821.08M)
Sales of Investments958M1.18B1.21B778M1.29B
Other Investing Activities(120.66M)(118.6M)000
Investing Cash Flow(144.83M)(139.96M)184.15M(140.24M)437.28M
Debt Repayment(26K)(28K)(10K)84.01M(460.97M)
Common Stock Issued4.55M5.22M4.42M4.15M9.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities21.18M10.3M11.38M2.16M(146K)
Financing Cash Flow25.7M15.49M15.79M90.32M(451.34M)
Effect of Forex Changes(188K)(97K)131K(174K)394K
Net Change in Cash(36.56M)(93.78M)126.73M(76.47M)(62.7M)
Free Cash Flow58.59M9.43M(100.43M)(69.22M)(75.68M)

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.